- Previous Close
1.2200 - Open
1.1800 - Bid 0.8928 x 200
- Ask 1.5600 x 200
- Day's Range
1.1800 - 1.2800 - 52 Week Range
0.9400 - 11.7600 - Volume
23,531 - Avg. Volume
192,558 - Market Cap (intraday)
64.566M - Beta (5Y Monthly) 1.67
- PE Ratio (TTM)
-- - EPS (TTM)
-1.5300 - Earnings Date Mar 4, 2025 - Mar 7, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
1.20
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.
www.shattucklabs.comRecent News: STTK
View MorePerformance Overview: STTK
Trailing total returns as of 3/4/2025, which may include dividends or other distributions. Benchmark is S&P 500 .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: STTK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: STTK
View MoreValuation Measures
Market Cap
63.02M
Enterprise Value
-23.43M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
9.25
Price/Book (mrq)
0.60
Enterprise Value/Revenue
18.32
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-41.07%
Return on Equity (ttm)
-71.09%
Revenue (ttm)
6.43M
Net Income Avi to Common (ttm)
-74.42M
Diluted EPS (ttm)
-1.5300
Balance Sheet and Cash Flow
Total Cash (mrq)
90.06M
Total Debt/Equity (mrq)
3.74%
Levered Free Cash Flow (ttm)
-35.13M